CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors

• Patricia Verduin, PhD, brings extensive science, technology, and sustainability expertise as well as business acumen to CMTA Board of Directors
• Patricia’s deep commitment to advancing technical innovation and solutions for improving the health and well-being of people and our planet further solidifies CMTA’s position as a global leader in research and patient support

GLENOLDEN, Pa., May 7, 2024 (Newswire.com) - The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of a respected leader in science, technology, and sustainability, Patricia Verduin, PhD, to its Board of Directors.

Renowned for her combination of technical depth and business acumen, Pat boasts a distinguished career dedicated to pioneering product innovations that enhance global health and environmental well-being. With a PhD in Food Chemistry from Rutgers University and an MBA from Fairleigh Dickinson University, her leadership spans prestigious board of director roles in Fortune 500 companies, including FMC Corporation, Ingredion Corporation, and Monsanto, among others. Pat’s tenure as Chief Science Officer at Colgate Palmolive, where she led a global team of scientists, engineers, designers, and regulatory and compliance specialists to develop innovative product solutions, underscores her commitment to driving impactful change, aligning seamlessly with CMTA's mission of improving the lives of all who have CMT.

"As someone deeply committed to fostering positive change and improving lives, I am honored to join the Charcot-Marie-Tooth Association's Board of Directors," said Pat. "My journey in global product development has instilled in me a profound appreciation for the transformative power of research and innovation and its impact on people. I am inspired by CMTA's leadership in supporting individuals affected by CMT while accelerating research to bring treatments, and I am eager to lend my expertise to further their mission. Together, we will continue to make meaningful strides towards improving the quality of life for those living with CMT and their families."

"We are delighted to welcome Dr. Verduin to CMTA’s Board of Directors," said Gilles Bouchard, CMTA Chairman of the Board. "Her expertise in science and technology, and her dedication to global health will greatly enhance our efforts to accelerate research and support the CMT community. We look forward to working with Pat to drive progress and foster hope for a brighter future for those living with CMT."

About CMT

Named after the three doctors who first described it in 1886: Charcot, Marie, and Tooth, CMT affects one in every 2,500 people—a rare disease subdivided into multiple subtypes, each with a lower prevalence. Due to the degradation of their nerves, people with CMT suffer lifelong progressive muscle weakness and atrophy of the arms and legs, and can affect other parts of the body. This leads to problems with balance, walking, hand use, and more. There currently is no treatment or cure for this debilitating disease.

About the Charcot-Marie-Tooth Association

The Charcot-Marie-Tooth Association is a community-led, community-driven 501(c)(3) nonprofit organization with a mission to support the development of new treatments for CMT, to improve the quality of life for people with CMT, and, ultimately, to find a cure. As the leading global philanthropic funder of CMT research, CMTA unites the community with clinicians and industry experts to accelerate the advancement of treatments, with investments of more than $24 million since 2008. For more information, visit https://www.cmtausa.org

Source: The Charcot-Marie-Tooth Association